HCW 바이올로직스(HCWB)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $2.68 (-8.38%), 시가총액 $0.01B, 52주 범위 $0.27 ~ $8.37.
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in phase 1 for alopecia areata diseases. The company also develops HCW9201, a fusion protein designed as a reagent to use in the production of natural killer (NK) cell-based therapies; HCW9206, a fusion protein designed as a reagent to use in the
HCW 바이올로직스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
HCW 바이올로직스의 현재 주가는 $2.68 (-8.38%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
HCW 바이올로직스의 시가총액은 약 $0.01B입니다.
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its